Ectopic Pregnancy Market Report 2026

The ectopic pregnancy market size has grown strongly in recent years. It will grow from $8.6 billion in 2025 to $9.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to pelvic inflammatory disease cases, delayed pregnancy diagnosis, assisted reproduction growth, emergency care demand, maternal health initiatives.

The ectopic pregnancy market size is expected to see strong growth in the next few years. It will grow to $11.31 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to early screening programs, minimally invasive treatments, reproductive health awareness, fertility clinic expansion, tele-gynecology services. Major trends in the forecast period include rising adoption of early diagnostic imaging, increased use of non-surgical medical management, growing awareness of early pregnancy complications, expansion of emergency gynecological care, improved access to fertility and reproductive health services.

The rising use of contraceptive devices is expected to drive the growth of the ectopic pregnancy market in the coming years. Contraceptive devices are designed to prevent pregnancy by either blocking fertilization or preventing the implantation of a fertilized egg. Their adoption is increasing due to heightened focus on family planning, population control, and the prevention of unintended pregnancies. However, higher usage of these devices, particularly intrauterine devices (IUDs), can inadvertently raise the risk of ectopic pregnancy if conception occurs, as IUDs may affect the normal passage of the egg through the fallopian tubes, potentially causing implantation outside the uterus. For instance, in February 2024, according to the Faculty of Sexual and Reproductive Healthcare (FSRH), a UK-based organization for family planning and sexual health, the use of long-acting reversible contraceptives (LARC) increased from 41.8 per 1,000 people in 2022 to 44.1 per 1,000 in 2023. Therefore, the growing adoption of contraceptive devices is driving the ectopic pregnancy market.

The increasing maternal age and trend of delayed pregnancies are expected to fuel the growth of the ectopic pregnancy market going forward. Maternal age and delayed pregnancies refer to women choosing to conceive later in life, which naturally raises pregnancy-related health risks, including complications such as ectopic pregnancy. This trend is growing as many women prioritize career and financial stability before starting a family, leading them to plan pregnancies later. Ectopic pregnancy underscores the elevated medical risks associated with later-age conception, highlighting the importance of timely monitoring and care in populations experiencing higher maternal age. For instance, in July 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, the birth rate for women aged 40-44 rose from 12.5 per 1,000 in 2023 to 12.7 per 1,000 in 2024, representing a 2% increase. Therefore, the rise in maternal age and delayed pregnancies is driving the growth of the ectopic pregnancy market.

Companies in the ectopic pregnancy market are increasingly developing artificial intelligence (AI)-powered ultrasound systems to improve diagnostic accuracy and patient outcomes. AI-powered ultrasound systems utilize machine learning algorithms to analyze ultrasound images, enhancing both the speed and precision of ectopic pregnancy diagnosis. For example, in April 2024, GE HealthCare, a US-based medical technology and diagnostics company, launched the Voluson Signature 20 and 18 ultrasound systems, integrating AI with advanced tools and ergonomic designs to shorten exam times for clinicians while providing clearer insights into women’s health. These systems combine high-performance hardware with flexible, scalable software to support clinicians in making more confident diagnostic and treatment decisions.

Major companies operating in the ectopic pregnancy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Fresenius Kabi USA, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA, H. Lundbeck A/S, Dr. Reddy's Laboratories, Hikma Pharmaceuticals Plc, Lupin Pharmaceuticals Inc., Zydus Pharmaceuticals.

North America was the largest region in the ectopic pregnancy market in 2025. The regions covered in the ectopic pregnancy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ectopic pregnancy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ectopic pregnancy market by increasing costs of imported diagnostic imaging equipment and pharmaceuticals. Hospitals and fertility centers in developed regions are most affected. These tariffs increase treatment costs by raising expenses for early diagnostic imaging and medical or surgical intervention, potentially affecting timely access to care. However, they support local production of reproductive health drugs, strengthening domestic pharmaceutical capabilities and improving supply stability for critical therapies.

The ectopic pregnancy market research report is one of a series of new reports that provides ectopic pregnancy market statistics, including ectopic pregnancy industry global market size, regional shares, competitors with a ectopic pregnancy market share, detailed ectopic pregnancy market segments, market trends and opportunities, and any further data you may need to thrive in the ectopic pregnancy industry. This ectopic pregnancy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ectopic pregnancy is a medical condition in which a fertilized egg implants and grows outside the uterus, most commonly in the fallopian tubes. This condition is serious and requires prompt medical attention, as the embryo cannot develop normally outside the uterus and may lead to life-threatening complications such as rupture and internal bleeding if untreated.

The main types of ectopic pregnancy include tubal ectopic pregnancy, non-tubal ectopic pregnancy, heterotopic ectopic pregnancy, and others. A tubal ectopic pregnancy occurs when a fertilized egg implants and begins to grow within the fallopian tubes, which carry eggs from the ovaries to the uterus. Treatments, such as folic acid analogues and corticosteroids, are distributed through channels including retail, online, and hospital pharmacies, serving hospitals, clinics, fertility centers, and other end users.

The ectopic pregnancy market consists of revenues earned by entities by providing services such as diagnostic services, emergency medical services, surgical services, and pharmacological treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ectopic pregnancy market also includes sales of ultrasound machines, hormone level monitoring kits, and medications such as methotrexate for medical management. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.